For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Carbetocin 100 µg | carbetocin 100 µg : Hemodynamic effect of | None | None | 0 | 25 | 9 | 25 | View |
| Oxytocin 5 u | oxytocin 5 u : Hemodynamic effect of | None | None | 0 | 26 | 9 | 26 | View |
| Placebo (NaCl) | placebo (NaCl) : Hemodynamic effect of | None | None | 0 | 25 | 2 | 25 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Feeling of warmth | None | Skin and subcutaneous tissue disorders | None | View |
| Chest pain | None | Cardiac disorders | None | View |
| Shortness of breath | None | Respiratory, thoracic and mediastinal disorders | None | View |
| Flushing | None | Skin and subcutaneous tissue disorders | None | View |
| Headache | None | Nervous system disorders | None | View |
| Nasal congestion | None | Skin and subcutaneous tissue disorders | None | View |
| Xerostomia | None | Gastrointestinal disorders | None | View |
| Palpitations | None | Cardiac disorders | None | View |
| Metallic taste | None | Nervous system disorders | None | View |